RxSight, Inc. reported that it has implanted 300,000 Light Adjustable Lens (LAL) devices since the product’s launch, a milestone announced on April 8 2026 that underscores the growing adoption of its post‑operative adjustable intra‑ocular lens technology.
The LAL platform, first introduced to surgeons in February 2020, has seen steady growth. In the fourth quarter of 2025, RxSight sold 28,611 LALs, a 10% sequential increase, and the full‑year 2025 total reached 109,615 units, up 12% from 2024. This expansion in LAL volume has helped offset a 48% decline in Light Delivery Device (LDD) system sales, the capital‑equipment component of the business.
Financially, the company posted Q4 2025 revenue of $32.6 million and a net loss of $9.2 million, or $0.22 per share. Full‑year 2025 revenue was $134.5 million with a net loss of $38.94 million. Gross profit margins improved to 77.5% in Q4 2025 from 71.6% a year earlier, driven by a favorable mix shift toward the higher‑margin LAL consumables.
Management highlighted the milestone’s significance: “The 300,000 milestone is a testament to the skill and dedication of the doctors who have leveraged LAL technology to deliver best‑in‑class clinical outcomes for patients and strong financial performance for their practices.” The company’s CEO also noted that the growing body of clinical evidence will be presented at ASCRS 2026, reinforcing the technology’s clinical credibility.
RxSight’s competitive landscape includes established premium IOL makers such as Alcon, Johnson & Johnson Vision, and Bausch + Lomb. The LAL’s unique post‑operative adjustability differentiates it from fixed‑power lenses offered by these competitors, positioning RxSight as a potential disruptor in the premium segment.
Looking ahead, RxSight has guided 2026 revenue to $120.0 million to $135.0 million, a slight decline at the midpoint compared with the prior year’s $134.5 million, largely due to anticipated lower LDD sales. Gross margin guidance remains in the 70%–72% range, reflecting confidence in maintaining pricing power as LAL adoption continues to grow.
The 300,000‑implant milestone, combined with improving margins and a clear path to recurring revenue from LAL consumables, signals a strengthening of RxSight’s business model and a potential shift toward a higher‑margin, subscription‑style revenue stream.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.